Definium Therapeutics (DFTX) Accumulated Expenses (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Accumulated Expenses data on file, last reported at $7.4 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 35.52% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 35.52% decrease from a year earlier, with the FY2025 full-year figure at $9.5 million, up 47.81% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $7.4 million, down from $9.5 million in the prior quarter.
• Over the last five years, Accumulated Expenses for DFTX reached as high as $19.0 million in Q3 2025 and fell as low as $3.2 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $9.0 million across 5 years, with a median of $8.2 million in 2024.
• On a YoY basis, Accumulated Expenses climbed as much as 263.79% in 2023 and fell as far as 53.1% in 2023.
• Year by year, Accumulated Expenses stood at $3.2 million in 2022, then soared by 263.79% to $11.6 million in 2023, then tumbled by 44.95% to $6.4 million in 2024, then jumped by 47.81% to $9.5 million in 2025, then slipped by 21.7% to $7.4 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $7.4 million in Q1 2026, $9.5 million in Q4 2025, and $19.0 million in Q3 2025.